clotrimazole ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
719 23593-75-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clotrimazole
  • lotrimin
  • rimazole
  • locasten
An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal CELL MEMBRANES. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane.
  • Molecular weight: 344.84
  • Formula: C22H17ClN2
  • CLOGP: 5
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 17.82
  • ALOGS: -5.37
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g V

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.07 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Feb. 3, 1975 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 690.29 13.51 231 12870 18677 56260289
Schizoaffective disorder 311.16 13.51 82 13019 2867 56276099
Drug level increased 175.54 13.51 89 13012 20636 56258330
Electrocardiogram QT prolonged 105.08 13.51 93 13008 54495 56224471
Chronic sinusitis 73.89 13.51 37 13064 8341 56270625
Vulvovaginal candidiasis 58.20 13.51 23 13078 2963 56276003
Paraesthesia oral 57.55 13.51 38 13063 14411 56264555
Procedural pain 53.46 13.51 38 13063 16233 56262733
Rheumatoid arthritis 51.25 13.51 13 13088 382591 55896375
Sinus rhythm 44.46 13.51 13 13088 668 56278298
Oral candidiasis 42.25 13.51 35 13066 18728 56260238
Eye infection toxoplasmal 40.16 13.51 10 13091 277 56278689
Vanishing bile duct syndrome 40.02 13.51 12 13089 673 56278293
Drug interaction 35.15 13.51 118 12983 209637 56069329
Endocrine ophthalmopathy 34.50 13.51 10 13091 498 56278468
Swelling of eyelid 34.42 13.51 15 13086 2470 56276496
Toxic shock syndrome 32.44 13.51 10 13091 616 56278350
Candida infection 31.13 13.51 34 13067 25633 56253333
Dyspepsia 30.62 13.51 63 13038 83408 56195558
Purpura senile 29.75 13.51 9 13092 520 56278446
Tongue blistering 27.76 13.51 11 13090 1426 56277540
Febrile neutropenia 26.91 13.51 69 13032 105476 56173490
Vulvovaginal inflammation 26.51 13.51 9 13092 754 56278212
Tarsal tunnel syndrome 25.37 13.51 8 13093 531 56278435
Glossodynia 25.11 13.51 3 13098 152455 56126511
Swollen tongue 24.98 13.51 33 13068 30291 56248675
Nasal ulcer 24.46 13.51 11 13090 1951 56277015
Therapeutic product effect decreased 24.16 13.51 5 13096 169447 56109519
Eyelid disorder 23.77 13.51 10 13091 1511 56277455
Angiodermatitis 22.92 13.51 5 13096 76 56278890
Mean cell haemoglobin increased 22.35 13.51 11 13090 2389 56276577
Aplastic anaemia 20.82 13.51 17 13084 8911 56270055
Post viral fatigue syndrome 20.58 13.51 6 13095 305 56278661
Pelvic pain 20.41 13.51 19 13082 11848 56267118
Drug ineffective 20.06 13.51 312 12789 918677 55360289
Dyslipidaemia 18.96 13.51 14 13087 6339 56272627
Resorption bone increased 18.81 13.51 8 13093 1242 56277724
Discomfort 18.59 13.51 5 13096 141756 56137210
Fungal infection 18.58 13.51 30 13071 32963 56246003
Vestibular disorder 18.36 13.51 8 13093 1317 56277649
Vaginal infection 18.15 13.51 14 13087 6763 56272203
Drug intolerance 18.09 13.51 21 13080 264797 56014169
Stevens-Johnson syndrome 17.65 13.51 24 13077 22639 56256327
Reperfusion arrhythmia 17.55 13.51 5 13096 234 56278732
Vulvovaginal discomfort 17.49 13.51 9 13092 2146 56276820
Toxicity to various agents 17.37 13.51 16 13085 224548 56054418
Conjunctivitis 15.41 13.51 20 13081 18040 56260926
Congenital absence of bile ducts 15.10 13.51 3 13098 28 56278938
Hepatic enzyme increased 14.75 13.51 11 13090 171373 56107593
Dysuria 14.73 13.51 26 13075 30703 56248263
SARS-CoV-2 test negative 14.17 13.51 5 13096 470 56278496
Oedema mouth 14.14 13.51 8 13093 2302 56276664
Neuropathy peripheral 13.89 13.51 54 13047 102839 56176127
Stoma site haemorrhage 13.86 13.51 6 13095 972 56277994
Vulvovaginal pain 13.85 13.51 8 13093 2394 56276572
Swelling face 13.60 13.51 36 13065 56033 56222933
Post transplant distal limb syndrome 13.59 13.51 4 13097 210 56278756

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Temperature regulation disorder 25.60 15.63 8 6206 614 31690516
Cellulitis 21.76 15.63 36 6178 47982 31643148
Hypoglycaemia neonatal 20.60 15.63 9 6205 1773 31689357
Pulmonary vasculitis 20.57 15.63 6 6208 364 31690766
Skin infection 20.15 15.63 14 6200 6849 31684281
Lip haemorrhage 20.05 15.63 7 6207 759 31690371
Rash pruritic 19.89 15.63 24 6190 23914 31667216
Accident 19.07 15.63 11 6203 3900 31687230
Aplastic anaemia 18.59 15.63 15 6199 9188 31681942
Microtia 17.58 15.63 5 6209 277 31690853
Congenital umbilical hernia 17.31 15.63 5 6209 293 31690837
Neuritis 16.84 15.63 6 6208 690 31690440
Lymphopenia 16.43 15.63 17 6197 14312 31676818
Fluid replacement 16.34 15.63 4 6210 123 31691007
Fungal infection 16.21 15.63 17 6197 14534 31676596
Leukopenia 15.84 15.63 35 6179 57793 31633337

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 67.52 13.37 33 15523 7495 70905393
Chronic sinusitis 66.80 13.37 34 15522 8417 70904471
Vulvovaginal candidiasis 64.74 13.37 23 15533 2343 70910545
Paraesthesia oral 54.95 13.37 37 15519 15380 70897508
Procedural pain 47.54 13.37 36 15520 17973 70894915
Oral candidiasis 47.08 13.37 41 15515 24911 70887977
Aplastic anaemia 41.02 13.37 32 15524 16684 70896204
Swelling of eyelid 35.56 13.37 16 15540 3016 70909872
Rheumatoid arthritis 35.53 13.37 10 15546 291795 70621093
Eye infection toxoplasmal 34.48 13.37 10 15546 530 70912358
Endocrine ophthalmopathy 34.14 13.37 10 15546 549 70912339
Vanishing bile duct syndrome 32.65 13.37 12 15544 1347 70911541
Toxic shock syndrome 32.10 13.37 11 15545 1007 70911881
Rash pruritic 29.47 13.37 51 15505 62940 70849948
Dyspepsia 29.20 13.37 62 15494 89015 70823873
Tongue blistering 28.84 13.37 11 15545 1368 70911520
Toxicity to various agents 28.69 13.37 25 15531 382147 70530741
Tarsal tunnel syndrome 26.35 13.37 8 15548 497 70912391
Purpura senile 26.26 13.37 8 15548 503 70912385
Candida infection 26.22 13.37 35 15521 34438 70878450
Nasal ulcer 25.92 13.37 11 15545 1802 70911086
Swollen tongue 25.74 13.37 36 15520 37010 70875878
Febrile neutropenia 24.38 13.37 99 15457 204219 70708669
Pelvic pain 23.85 13.37 20 15536 11540 70901348
Eyelid disorder 23.59 13.37 10 15546 1634 70911254
Angiodermatitis 23.34 13.37 5 15551 74 70912814
Overdose 22.22 13.37 5 15551 169740 70743148
Stevens-Johnson syndrome 22.18 13.37 33 15523 35874 70877014
Drug ineffective 21.44 13.37 120 15436 939632 69973256
Therapeutic product effect decreased 21.35 13.37 3 15553 143015 70769873
Post viral fatigue syndrome 20.78 13.37 6 15550 313 70912575
Dyslipidaemia 20.22 13.37 17 15539 9843 70903045
Gingival swelling 19.92 13.37 12 15544 4117 70908771
Vaginal infection 19.60 13.37 13 15543 5265 70907623
Mean cell haemoglobin increased 18.85 13.37 11 15545 3562 70909326
Pruritus 18.84 13.37 135 15421 345425 70567463
Resorption bone increased 18.47 13.37 8 15548 1377 70911511
Fungal infection 18.39 13.37 31 15525 37436 70875452
Vulvovaginal inflammation 18.22 13.37 6 15550 486 70912402
Pulmonary vasculitis 18.21 13.37 6 15550 487 70912401
Urinary tract infection 17.73 13.37 104 15452 248665 70664223
Vulvovaginal discomfort 17.11 13.37 8 15548 1647 70911241
Wound complication 16.95 13.37 11 15545 4298 70908590
Reperfusion arrhythmia 16.85 13.37 5 15551 287 70912601
Oral mucosal blistering 16.67 13.37 12 15544 5544 70907344
Lip haemorrhage 16.35 13.37 7 15549 1172 70911716
Vulvovaginal pain 16.01 13.37 8 15548 1903 70910985
Plicated tongue 15.87 13.37 4 15552 124 70912764
Vulvovaginal mycotic infection 15.23 13.37 10 15546 3985 70908903
Genital rash 14.74 13.37 6 15550 886 70912002
Vestibular disorder 14.55 13.37 8 15548 2312 70910576
Swelling face 14.22 13.37 38 15518 63126 70849762
Kidney transplant rejection 14.20 13.37 14 15542 9947 70902941
Fluid replacement 14.02 13.37 4 15552 200 70912688
Eye infection 14.01 13.37 14 15542 10104 70902784
Accident 13.79 13.37 12 15544 7279 70905609
Post transplant distal limb syndrome 13.60 13.37 5 15551 562 70912326
Nephrogenic systemic fibrosis 13.59 13.37 11 15545 6041 70906847
Vasculitis 13.57 13.37 19 15537 19539 70893349
Cellulitis 13.47 13.37 50 15506 98878 70814010

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A01AB18 ALIMENTARY TRACT AND METABOLISM
STOMATOLOGICAL PREPARATIONS
STOMATOLOGICAL PREPARATIONS
Antiinfectives and antiseptics for local oral treatment
ATC D01AC01 DERMATOLOGICALS
ANTIFUNGALS FOR DERMATOLOGICAL USE
ANTIFUNGALS FOR TOPICAL USE
Imidazole and triazole derivatives
ATC G01AF02 GENITO URINARY SYSTEM AND SEX HORMONES
GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
Imidazole derivatives
FDA CS M0002083 Azoles
FDA EPC N0000175487 Azole Antifungal
CHEBI has role CHEBI:35441 antiinfective agents
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:78298 environmental contaminants
MeSH PA D058888 14-alpha Demethylase Inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000891 Anti-Infective Agents, Local
MeSH PA D000935 Antifungal Agents
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006727 Hormone Antagonists
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D065088 Steroid Synthesis Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Tinea pedis indication 6020002 DOID:12403
Candidiasis of skin indication 49883006
Pityriasis versicolor indication 56454009 DOID:9060
Candidal vulvovaginitis indication 72605008 DOID:2272
Candidiasis of mouth indication 79740000 DOID:14262
Tinea corporis indication 84849002
Diaper rash indication 91487003
Tinea cruris indication 399029005
Prevention of Oropharyngeal Candidiasis indication
Oropharyngeal Candidiasis indication
Paronychia off-label use 71906005 DOID:13117
Telangiectasia disorder contraindication 247479008
Abdominal pain - cause unknown contraindication 314212008
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Atrophoderma contraindication 399979006
Peripheral vascular disease contraindication 400047006




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Cats Fungal infections caused by Microsporum canis Indication
Cats Fungal infections caused by Trichophyton mentagrophytes Indication
Cats Otitis externa caused by yeast, Malassezia pachydermatis Indication
Dogs Fungal infections caused by Microsporum canis Indication
Dogs Fungal infections caused by Trichophyton mentagrophytes Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Veltrim 1% Dermatologic Cream Elanco US Inc. 1
Otomax Intervet Inc. 3
Mometamax Otic Suspension Intervet Inc. 3
Tri-Otic Ointment Med-Pharmex Inc. 3
Vetro-Max Fougera Pharmaceuticals Inc. 3
GBC Ointment Cronus Pharma Specialities India Private Limited 3
Mometavet Med-Pharmex Inc. 3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.4 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR Ki 5.19 DRUG MATRIX
Prostaglandin G/H synthase 2 Enzyme IC50 4.38 DRUG MATRIX
Nuclear receptor subfamily 1 group I member 3 Nuclear hormone receptor ANTAGONIST IC50 6.16 IUPHAR
Mu-type opioid receptor GPCR Ki 6.14 DRUG MATRIX
D(1A) dopamine receptor GPCR Ki 5.35 DRUG MATRIX
D(2) dopamine receptor GPCR Ki 5.39 DRUG MATRIX
Adenosine receptor A2a GPCR Ki 5.15 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 5.35 DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.52 CHEMBL
Cytochrome P450 3A4 Enzyme IC50 7.70 WOMBAT-PK
Multidrug resistance protein 1 Transporter IC50 5.17 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter Ki 5.51 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.10 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 5.00 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 5.50 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 5.13 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 5.12 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.24 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 5.43 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.05 DRUG MATRIX
Histamine H1 receptor GPCR Ki 5.47 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 5.78 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 5.29 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 5.68 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 5.79 DRUG MATRIX
Glucocorticoid receptor Nuclear hormone receptor Ki 5.83 DRUG MATRIX
Beta-3 adrenergic receptor GPCR Ki 5.27 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.35 DRUG MATRIX
Adenosine receptor A1 GPCR Ki 5.11 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.57 DRUG MATRIX
Intermediate conductance calcium-activated potassium channel protein 4 Ion channel IC50 7.15 CHEMBL
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor WOMBAT-PK
D(4) dopamine receptor GPCR Ki 5.16 DRUG MATRIX
Carbonic anhydrase 2 Enzyme IC50 4.52 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 5.13 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 5.60 DRUG MATRIX
Delta-type opioid receptor GPCR Ki 5.76 DRUG MATRIX
Acetylcholinesterase Enzyme IC50 4.71 DRUG MATRIX
Cytochrome P450 2C9 Enzyme IC50 7.80 DRUG MATRIX
Platelet-activating factor receptor GPCR Ki 4.65 DRUG MATRIX
Aromatase Enzyme IC50 8.74 CHEMBL
Cysteinyl leukotriene receptor 1 GPCR Ki 4.78 CHEMBL
Epidermal growth factor receptor Kinase IC50 4.16 DRUG MATRIX
Vasopressin V2 receptor GPCR IC50 5.60 CHEMBL
Substance-P receptor GPCR Ki 5.06 DRUG MATRIX
Steroid 17-alpha-hydroxylase/17,20 lyase Enzyme IC50 7.09 WOMBAT-PK
Potassium voltage-gated channel subfamily A member 3 Ion channel IC50 5.22 CHEMBL
Cytochrome P450 2C19 Enzyme IC50 7.80 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 4.50 DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 4.18 DRUG MATRIX
Thromboxane-A synthase Enzyme IC50 7.85 DRUG MATRIX
Bile acid receptor Nuclear hormone receptor IC50 5.49 CHEMBL
Lanosterol 14-alpha demethylase Enzyme IC50 6.89 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.92 CHEMBL
Substance-K receptor GPCR Ki 5.47 DRUG MATRIX
Transient receptor potential cation channel subfamily M member 2 Ion channel IC50 5.52 CHEMBL
C-C chemokine receptor type 4 GPCR IC50 5.80 CHEMBL
C-X-C chemokine receptor type 1 GPCR IC50 5.70 CHEMBL
Transitional endoplasmic reticulum ATPase Enzyme IC50 5.85 CHEMBL
Malate dehydrogenase cytoplasmic Enzyme IC50 4.46 CHEMBL
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase Enzyme IC50 6.10 CHEMBL
Histamine H2 receptor GPCR Ki 5.29 DRUG MATRIX
Lanosterol 14-alpha demethylase Enzyme INHIBITOR CHEMBL CHEMBL
Beta-lactamase Enzyme IC50 4.70 CHEMBL
Androgen receptor Transcription factor Ki 5.11 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 4.91 DRUG MATRIX
Cysteinyl leukotriene receptor 1 GPCR Ki 4.78 DRUG MATRIX
Progesterone receptor Transcription factor Ki 5.94 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 4.58 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 4.75 CHEMBL
Lanosterol 14-alpha demethylase Enzyme Kd 6.70 CHEMBL
14-alpha sterol demethylase Cyp51A Enzyme Kd 5.32 CHEMBL
14-alpha sterol demethylase Enzyme Kd 6.99 CHEMBL
Indoleamine 2,3-dioxygenase 2 Enzyme IC50 5.23 CHEMBL
Mycocyclosin synthase Enzyme Kd 7.14 CHEMBL
Putative cytochrome P450 130 Enzyme Kd 4.88 CHEMBL
Alpha-chymotrypsin Enzyme IC50 4.07 CHEMBL
Indoleamine 2,3-dioxygenase 1 Enzyme IC50 4.29 CHEMBL
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Enzyme Ki 4.46 CHEMBL

External reference:

IDSource
4018265 VUID
N0000146595 NUI
D00282 KEGG_DRUG
202859 RXNORM
4018265 VANDF
C0009074 UMLSCUI
CHEBI:3764 CHEBI
CL6 PDB_CHEM_ID
CHEMBL104 ChEMBL_ID
DB00257 DRUGBANK_ID
D003022 MESH_DESCRIPTOR_UI
2812 PUBCHEM_CID
2330 IUPHAR_LIGAND_ID
2912 INN_ID
G07GZ97H65 UNII
1284 MMSL
4482 MMSL
d01236 MMSL
002916 NDDF
387325003 SNOMEDCT_US
5797005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Clotrimazole HUMAN PRESCRIPTION DRUG LABEL 1 0054-4146 LOZENGE 10 mg ORAL ANDA 14 sections
Clotrimazole HUMAN PRESCRIPTION DRUG LABEL 1 0054-4146 LOZENGE 10 mg ORAL ANDA 14 sections
Clotrimazole HUMAN PRESCRIPTION DRUG LABEL 1 0054-8146 LOZENGE 10 mg ORAL ANDA 14 sections
Clotrimazole HUMAN PRESCRIPTION DRUG LABEL 1 0054-8146 LOZENGE 10 mg ORAL ANDA 14 sections
Lotrisone HUMAN PRESCRIPTION DRUG LABEL 2 0085-0924 CREAM 10 mg TOPICAL NDA 26 sections
Good Sense Athletes Footantifungal HUMAN OTC DRUG LABEL 1 0113-0857 CREAM 1 g TOPICAL OTC monograph final 13 sections
Clotrimazole HUMAN PRESCRIPTION DRUG LABEL 1 0168-0133 CREAM 10 mg TOPICAL ANDA 20 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0168-0258 CREAM 10 mg TOPICAL ANDA 27 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0168-0370 LOTION 10 mg TOPICAL ANDA 20 sections
Fungicure Liquid Gel HUMAN OTC DRUG LABEL 1 0295-1363 LIQUID 10 mg TOPICAL OTC monograph final 9 sections
Fungicure Manicure Pedicure Anti Fungal HUMAN OTC DRUG LABEL 1 0295-6307 LIQUID 1 mg TOPICAL OTC monograph final 10 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0363-0220 CREAM 10 mg VAGINAL ANDA 16 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0363-0220 CREAM 10 mg VAGINAL ANDA 16 sections
WALGREENS CLOTRIMAZOLE HUMAN OTC DRUG LABEL 1 0363-1299 CREAM 1 g TOPICAL OTC monograph final 11 sections
athletes foot HUMAN OTC DRUG LABEL 1 0363-1857 CREAM 1 g TOPICAL OTC monograph final 13 sections
Walgreens Clotrimazole 3 HUMAN OTC DRUG LABEL 1 0363-2062 CREAM 2 g VAGINAL NDA 16 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0363-2105 CREAM 10 mg TOPICAL OTC MONOGRAPH FINAL 14 sections
Ringworm HUMAN OTC DRUG LABEL 1 0363-2107 CREAM 10 mg TOPICAL OTC MONOGRAPH FINAL 14 sections
Walgreens Jock Itch HUMAN OTC DRUG LABEL 1 0363-2109 CREAM 10 mg TOPICAL OTC MONOGRAPH FINAL 14 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0363-3492 LIQUID 1 mg TOPICAL OTC monograph final 8 sections
Walgreens Clotrimazole Antifungal HUMAN OTC DRUG LABEL 1 0363-7412 CREAM 1 g TOPICAL OTC monograph final 11 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0472-0220 CREAM 10 mg VAGINAL ANDA 16 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0472-0220 CREAM 10 mg VAGINAL ANDA 16 sections
ClotrimazoleAntifungal HUMAN OTC DRUG LABEL 1 0472-0350 CREAM 10 mg TOPICAL OTC monograph final 13 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0472-0379 CREAM 10 mg TOPICAL ANDA 24 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0536-1181 SOLUTION 1 g TOPICAL OTC monograph final 13 sections
Rugby Clotrimazole Antifungal Cream HUMAN OTC DRUG LABEL 1 0536-1265 CREAM 1 g TOPICAL OTC monograph final 12 sections
RUGBY ANTIFUNGAL CLOTRIMAZOLE HUMAN OTC DRUG LABEL 1 0536-1272 CREAM 0.01 g TOPICAL OTC monograph final 14 sections
Clotrimazole HUMAN PRESCRIPTION DRUG LABEL 1 0574-0107 LOZENGE 10 mg ORAL ANDA 18 sections
Major Clotrimazole HUMAN OTC DRUG LABEL 1 0904-7822 CREAM 10 mg TOPICAL OTC monograph final 11 sections